Know Cancer

or
forgot password

A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes


Phase 1/Phase 2
16 Years
N/A
Not Enrolling
Both
Myelodysplastic Syndrome

Thank you

Trial Information

A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes


Inclusion Criteria:



- MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long
as their IPSS score ≤ 1.5.

Exclusion Criteria:

- Pregnant women and nursing women will be excluded.

- History of clinically significant liver or kidney disease.

- ECOG>2

- IPSS score >1.5

- Poorly controlled diabetes mellitus, hypertension, or other serious medical or
psychiatric illness that could potentially interfere with the completion of treatment
according to the protocol.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

major hematologic improvement in any lineage

Principal Investigator

moshe e gatt, dr

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hadassah Medical Organization

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

385-mds 1-HMO-CTIL

NCT ID:

NCT00247026

Start Date:

April 2007

Completion Date:

Related Keywords:

  • Myelodysplastic Syndrome
  • myelodysplasia
  • curcumin
  • coenzyme Q10
  • cytopenia
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location